# Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

> **NCT05461430** · — · COMPLETED · sponsor: **Travera Inc** · enrollment: 72 (actual)

## Conditions studied

- Pleural Effusion, Malignant
- Ascites, Malignant
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Carcinoma, Renal
- Carcinoma, Small Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Pancreatic Ductal
- Carcinoma, Neuroendocrine
- Carcinoma, Thymic
- Carcinoma, Pancreatic
- Carcinoma Breast
- Carcinoma, Ovarian
- Carcinoma Bladder
- Carcinoma of Unknown Primary
- Carcinoma of the Head and Neck
- Carcinoma of the Oropharynx
- Carcinoma of the Larynx
- Carcinoma of the Bladder
- Carcinoma of Esophagus
- Carcinoma of the Nasopharynx
- Carcinoma of the Penis
- Carcinoma of the Cervix
- Carcinoma of the Anus
- Carcinoma of the Vulva
- Carcinoma of the Appendix
- Carcinoma of the Oral Cavity
- Cholangiocarcinoma
- Melanoma
- Mesothelioma
- Pancreatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05461430
- **Lead sponsor:** Travera Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-15
- **Primary completion:** 2026-03-23
- **Final completion:** 2026-03-23
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461430, "Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05461430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*